Abstract library

186 results for "Gomes".
#1349 Access to Care and Outcomes for Neuroendocrine Tumors: Does Socio-Economic Status Matter? A Population-Based Analysis.
Introduction: Neuroendocrine Tumors (NET) lack standardized care. Differences in socioeconomic status (SES) worsen the impact of non-standardized care.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Hallet Julie
#2144 Analysis of the Proteomics of Serum Circulating Exosomes in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms
Introduction: Gastro-entero-pancreatic neuroendocrine neoplasms(GEP-NENs) are intractable, heterogeneous tumors, characterized by secreting serotonin metabolites or polypeptide hormones. There are currently little targets for the diagnosis and treatment of GEP-NENs. Serum circulating exosomes (scrExos) are extracellular vesicles secreted by all cells especially neuroendocrine cells to some extent, circulating in the blood with proteins and nucleic acids.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Bai Jian-An
Authors: Jian-An B, Qiyun T, Ye T, ...
#402 Single-Center Treatment Outcomes in Patients (pts) with High Grade Neuroendocrine Carcinoma of the Uterine Cervix (cNEC)
Introduction: cNEC is a rare and aggressive cancer; the best treatment is unknown.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Boris Naraev
#2173 Decreased Serum Amyloid A1 as Potential Diagnostic Marker for Gastro-Entero-Pancreatic Neuroendocrine Neoplasms
Introduction: Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) are rare tumors with an increased incidence reported in recent years. Researchers have shown that tumor cells produce and secrete more exosomes compared with normal cells. Serum amyloid A1 (SAA1) is elevated in patients with liver cancer, lung cancer, breast cancer, prostate cancer and endometrial cancer. However, the relation between SAA1 and GEP-NENs remains unclear.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: He Na
Authors: Na H, Qiyun T, ...
#1773 Clinical Outcomes of Systemic Chemotherapy in Patients with High Grade Neuroendocrine Carcinoma of Biliary Tract
Introduction: : Neuroendocarine tumor of biliary tract is very rare and clinical outcomes of advanced neuroendocrine tumors of biliary tract has not been well demonstrated.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: MD Changhoon Yoo
Authors: Yoo C, Lee K, Kim K P, Chang H M, ...
#1809 What Do We Know About Carcinoid Heart Disease? A Systematic Literature Review
Introduction: Carcinoid heart disease (CHD) is a life-threatening complication of carcinoid syndrome (CS).
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Olga Ovcinnikova
#249 Management of Insulinomas: Perioperative and Long-term Outcomes Following Enucleations and Pancreatic Resections in 198 Patients
Introduction: Enucleation represents the procedure of choice for the treatment of insulinomas. Considering the site and the number of lesions, however, formal pancreatic resection may be necessary.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Stefano Crippa
#1144 Aggressive Multi-Modality Treatment of Pancreatic Neuroendocrine Tumors (pNETs): Outcomes in Patients with Advanced Disease
Introduction: pNETs carry the worst prognosis of all NETs, particularly when hepatic metastasis are present. We try to actively treat all patients referred.
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: Damian Mayo
Authors: Mayo D, Armstrong T, Cave J, Nolan L, ...
#1194 Chromogranin A (CgA) and PFS Outcomes in Lanreotide Autogel (LAN) in Patients with Metastatic Enteropancreatic (EP-) NETs: Data from the CLARINET Study
Introduction: The CLARINET study showed LAN 120 mg prolonged PFS vs. placebo (PBO) in patients with metastatic EP-NETs.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Martyn Caplin
Authors: Caplin M, Pavel M, Cwikla J B, Phan A T, ...
Keywords: lanreotide, biomarker
#1352 Outcomes of Cytoreductive Surgery for Well-Differentiated Metastatic Neuroendocrine Tumors in the Setting of Extra-Hepatic Metastases
Introduction: Cytoreduction with extra-hepatic disease for neuroendocrine tumors (NET) remains controversial
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: Hallet Julie